Press releases

30 November, 2017

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in ...

3 November, 2017

Regulatory

NeuroVive conducts a directed new share issue of SEK 5.3 Million

Lund, Sweden, 3 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directe ...

31 July, 2017

Regulatory

Number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, July 31, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in Ne ...

18 July, 2017

Regulatory

NeuroVive signs private placement agreement with Esousa Holdings LLC and issues units

Lund, Sweden, 18 July 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) is pleased to announce that it has signed a non-brokered private placement agreement (the "Placement") wi ...

31 March, 2017

Regulatory

Number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, March 31, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in N ...

15 August, 2016

Regulatory

NeuroVive completes 10 percent acquisition of Isomerase Therapeutics

Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced ...

2 June, 2016

Regulatory

NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded to trading on the OTC Market Group's best market, OTCQX in the US. The ...

31 May, 2016

Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...

23 May, 2016

Regulatory

Updated timeline for conversion of NeuroVive’s BTUs into shares and warrants

NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of Neuro ...

10 May, 2016

Regulatory

NeuroVive preferential rights issue fully subscribed

NeuroVive Pharmaceutical AB (publ) has completed the preferential rights issue of units, comprising shares and warrants, authorized by the Extraordinary General Meeting on 31 March 2016. The preferent ...

14 April, 2016

Regulatory

NeuroVive publishes prospectus and announces new publication date of the Q1 interim report

On 28 February 2016, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to carry out a new issue of shares and warrants (units) with preferential rights for the company ...

29 February, 2016

Regulatory

NeuroVive resolves on rights issue totaling approximately SEK 94.4 million for continued development of the project portfolio

On 28 February 2016, The Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") decided to carry out a new issue of shares and warrants (units) with preferential right ...